Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0JC1Z | ISIN: FR0010282822 | Ticker-Symbol: S4M
Tradegate
17.01.25
08:03 Uhr
166,30 Euro
-2,20
-1,31 %
1-Jahres-Chart
VUSIONGROUP Chart 1 Jahr
5-Tage-Chart
VUSIONGROUP 5-Tage-Chart
RealtimeGeldBriefZeit
167,80168,8013:04
167,70169,3017.01.
Actusnews Wire
722 Leser
Artikel bewerten:
(2)

SESIM (management holding company of VusionGroup): Financing and share reclassification transactions

Finanznachrichten News

VusionGroup has been informed that SESIM, the management holding company owning 12% of VusionGroup and majority owned by VusionGroup management and employees, has carried out a bank financing transaction, combined with a reclassification of SESIM shares between certain shareholders and SESIM.

Following this transaction, SESIM retains 12% of VusionGroup's capital and voting rights, and the shareholding in SESIM held by some of SESIM's main shareholders who are also VusionGroup managers or directors has been strengthened.

The transactions, which were approved by SESIM's Board of Directors, included the following:

  • Financing of SESIM :
    • A new €20 million bank loan, enabling SESIM to buy back its own shares from certain sellers, which were then cancelled.
  • Reclassification of SESIM shares :
    • Reclassification operations enabled 19 existing SESIM shareholders to sell part of their shares, and 32 existing and new shareholders (all VusionGroup managers, employees or directors) to invest in or increase their stake in SESIM.
    • These transactions were carried out based on a price per SESIM share calculated on the basis of VusionGroup average share price over the 60 days preceding the SESIM Board of Directors' meeting which approved the transaction, adjusted for debt and a discount for illiquidity.
    • In particular :
      • Parmen, a holding company equally owned by Thierry Gadou, Chairman and CEO of VusionGroup, and Philippe Bottine, Deputy CEO of VusionGroup, sold 310,000 SESIM shares to repay a €2 million bond loan contracted by Parmen in 2017 to invest in SESIM and maturing in 2024. These shares were bought back by SESIM and cancelled. As a result of this transaction and the accretive effect of the cancelled shares, Thierry Gadou's direct and indirect interest in SESIM increased from 6.98% to 7.09%.
      • Peter Brabeck-Letmathe, Vice-Chairman of the Board of Directors of VusionGroup, acquired 1,866,252 shares for €12 million, increasing his stake in SESIM from 4.47% to 11.17%.
      • Hélène Ploix, director of VusionGroup, acquired 46,656 shares, increasing her stake from 0.48% to 0.68%.
      • Thierry Lemaitre, CFO of VusionGroup, did not sell any shares, although his stake increased from 4.93% to 5.38% due to share cancellations.
      • No SESIM shareholder who is still an employee of the Group sold more than 30% of his or her stake in SESIM on this occasion.

Following these transactions, no director of VusionGroup holds directly or indirectly via SESIM more than 10% of the capital of VusionGroup.

It is also planned to carry out this type of transaction on a regular basis in the future, to offer an opportunity for liquidity or investment in SESIM to existing or new shareholders (managers, employees or directors of VusionGroup).

As a reminder, SESIM was created in 2017 to federate the management's shareholding base for the long term horizon of the Vusion '27 plan, at which point the VusionGroup shares held by SESIM could be transferred in full to SESIM shareholders.

About VusionGroup

VusionGroup is the global leader in the digitalization solutions for commerce, serving over 350 large retailer groups around the world in Europe, Asia and North America. The Group develops technologies that create a positive impact on society by enabling sustainable and human-centered commerce.

By leveraging our IoT & Data technologies, we empower retailers to re-imagine their physical stores into efficient, intelligent, connected, and data-driven assets. We unlock higher economic performance, facilitate seamless collaboration across the value chain, enhance the shopping experience, create better jobs, cultivate healthier communities, and significantly reduce waste and carbon emissions.

VusionGroup consist of six families of solutions, harnessing the full potential of IoT, Cloud, Data, and artificial intelligence (AI) technologies, at the service of the modernization of commerce: SESimagotag (ESL & Digital Shelf Systems), VusionCloud, Captana (computer vision and artificial intelligence platform), Memory (data analytics), Engage (retail media and in-store advertising), and PDidigital (logistics and industrial solutions).

VusionGroup supports the United Nations' Global Compact initiative and has received in 2023 the Platinum Sustainability Rating from EcoVadis, the world's reference of business sustainability ratings.

VusionGroup is listed in compartment A of Euronext Paris and member of the SBF120 Index.?Ticker: VU - ISIN code: FR0010282822 - Reuters: VU.PA - Bloomberg: VU.FP

www.vusion.com

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: xm1vk8VvYpyZlWmelsuZaZeUmm2WmmGXmpeYlmebY5eVmW1mymeXbZvLZnFol2tr
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-87265-vusiongroup_sesim_august2024.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.